Substantia nigra area evaluated by neuromelanin-sensitive MRI as an imaging biomarker of disease progression in Parkinson's disease by Fabbri, Margherita et al.
Substantia nigra area evauated by neuromelanin-sensitive MRI as an imaging biomarker of disease progression in Parkinson's disease
Margherita Fabbri1, MD, Sofia Reimão1,2 MD, PhD, Miguel Carvalho3, Rita G Nunes 3,4, Daisy Abreu1, Leonor Correia Guedes1,5, MD, Raquel Bouça1, Patricia P Lobo1, MD, Catarina Godinho1, 6,7 PhD, Miguel 
Coelho1,5, MD, PhD, Nilza C Gonçalves1, Mario Miguel Rosa1, 7, MD, PhD, Angelo Antonini8, MD, PhD, Joaquim J Ferreira1, 7,9, MD, PhD
1Clinical Pharmacology Unit, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon, Portugal; 2Neurological Imaging Department, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal; 
3Instituto de Biofísica e Engenharia Biomédica, Faculdade de Ciências, University of Lisbon, Lisbon, Portugal; 4Department of Bioengineering and Institute for Systems and Robotics (ISR/IST), LARSyS, Instituto Superior Técnico, University of 
Lisbon, Lisbon, Portugal; 5Department of Neurosciences, Hospital Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal; 6Center for Interdisciplinary Research Egas Moniz (CiiEM), Instituto Superior de Ciências da Saúde Egas Moniz, 
Monte de Caparica, Portugal; 7CNS – Campus Neurológico Sénior, Torres Vedras, Portugal; 8Fondazione Ospedale San Camillo"-I.R.C.C.S., Parkinson and Movement Disorders Unit, Venice, Italy; 9Laboratory of Clinical Pharmacology and 
Therapeutics, Faculty of Medicine, University of Lisbon, Lisbon, Portugal
BACKGROUND
OBJECTIVE
CONCLUSION
A specific T1-weighted magnetic resonance 
imaging (MRI) sequence has been shown to 
detect substantia nigra (SN) neuromelanin (NM) 
signal changes that accurately discriminate 
Parkinson’s disease (PD) patients from controls, 
even in early disease stages. However, it is 
unclear what happens to these SN changes in 
later disease stages
To investigate the pattern of SN-NM area loss and 
contrast ratio (CR) intensity changes in late-stage 
Parkinson’s disease (LSPD) patients, compared to 
de novo PD patients and PD patients with a 2-5 
year disease duration in order to evaluate NM 
changes throughout disease progression.
METHODS
A comparative cross-sectional study was 
performed, analyzing SN-NM MRI signals in late 
stage PD patients (LSPD) (Schwab and England 
Activities of Daily Living Scale score <50 or Hoehn 
Yahr Stage [HY] >3), comparing them with other 
disease stages, i.e. de novo (untreated patients; 
disease duration < 6 months) and 2-5 year PD 
and controls. 
For all groups SN-NM signal area and contrast 
ratio (CR) values (Figure 1) for the internal and 
lateral SN regions were obtained with semi-
automated methods. 
RESULTS
13 LSPD, 12 de novo patients with PD, 10 PD patients with a 2-5 year 
disease duration, and 10 controls were included (Table 1).
LSPD patients had a median disease duration of 14 years [IQR: 9-17]. They 
were significantly older compared to controls and de novo PD patients and 
had a worse HY stage and MDS-UPDRS part II compared to the de novo and 
2-5 year PD groups. 
NM signal area was significantly decreased in de novo PD compared to 
LSPD (Figure 2 and 3)  (P-value = 0.005; sensitivity: 75%; specificity 92% and 
AUC: 0.86) (Figure 4, Pannel B).
In the lateral SN region, a decrease in the CR was detected in all PD groups 
compared to controls; despite not reaching statistical significance, a slight 
increment was observed comparing LSPD to 2-5 year PD (Figure 5).
NM signal area significantly correlated with HY (R=-0.37; P<0.05) and 
MDS-UPDR part II (R=-0.4; P <0.05) while a weak correlation was found with 
MDS-UPDRS part III (R=-0.26; P: 0.1).
A moderate correlation was found between age and CRl (R= - 0.42; 
P<0.05) and CRi (R=-0.36; P<0.05). No correlations were found between HY, 
MDS-UPDRS part II, MDS-UPDRS part III, LEDD and CRl or CRi. 
In the present study, with semi-automated MRI measures, we detected 
a stage-dependent progressive decrease in the SN-NM area of PD 
patients. 
A marked SN-NM area decrease occurred in parallel with other markers 
of disease severity. 
Our findings suggest that NM-sensitive MRI could be used as a potential 
biomarker for nigral degeneration and disease progression in PD patients. 
CR values, although showing a tendency for a decrease with disease 
progression, presented a slight, albeit not significant, increase in the LSPD 
group; its interaction with therapeutic intervention and its modifications 
with disease progression needs further investigation.
This is the first study that observed SN-NM area modifications in a 
sample of LSPD patients, allowing an assessment of the modifications of 
NM signal in very late disease stage. 
Figure 1. Representative CR assessment by means 
of circular regions of interest (ROIs) on an NM-
sensitive T1-weighted MRI. CCr: crus cerebri right; 
CCL: crus cerebri left; SNiL: substantia nigra, left 
internal region; SNlL: substantia nigra, left lateral 
region; SNiR: substantia nigra, right internal 
region; SNlR: substantia nigra, right lateral region.
Healthy subjects De novo PD 2-5 year PD LSPD P value
Number (female/male) 10 (4/6) 12 (7/5) 9 (2/7) 13 (7/6) 0.3
Age, yrs 60 [55-69.2] 62.5 [52.5 – 73.7 ] 66 [63.5 – 71.2] 78 [68.5-81.5] a, f: 1; b: 0.8; c: 
0.001; d: 0.003; e: 
0.08;
HY NA 2 2 4 d - e: <0.001
LEDD NA 0 480 [325-810] 1040 [725-1325] e <0.01 
MDS-UPDRS part II NA 6.2 [3.5 – 10.6] 10.1 [1.7 – 12.8] 36 [30-40.5] d-e: <0.001; f: 0.1
MDS-UPDRS part III NA 32.3 [28.7 – 47] 24.5 [13.4 – 43.1] 51 [41-53.5] f: 1;  e: 0.02; d: 
0.09;
Area (〖mm〗^2 ) 40.63 [33.03-55.64] 27.7 [17.13-360.4] 22.65 [8.64- 46.84] 18.68 [12.50 – 26.47] a: 0.002; b, c 
<0.001; d: 0.005; e: 
1; f: 0.8;
CR
Internal region
1.16 [1.11 – 1.19] 1.15 [1.09 – 1.21] 1.12 [1.05 – 1.16] 1.12 [1.09 – 1.18] 0.06
CR
Lateral region
1.10 [1.02 – 1.12] 1.06 [0.10 – 1.13] 1.03 [0.99 – 1.08] 1.04 [0.10 – 1.1] b: 0.008; a,c:0.1; 
d,e,f: 1;
Table 1. Demographic, clinical and neuromelanin assessment data of patients and controls. Values are presented as median [IQR: 25th - 75th percentile] if not 
otherwise specified. NA: not available; LEDD: levodopa equivalent daily dose. CR: contrast ration. HY: Hoehn and Yahr rating scale; MDS-UPDRS: Movement 
disorders society Unified Parkinson’s disease Rating Scale Comparisons: a) controls versus de novo PD; b) controls versus 2-5 yrs PD; c) controls versus LSPD; d) 
de novo PD versus LSPD; e) 2-5 yrs versus LSPD; f: de novo PD versus 2-5 yrs PD. Statistical significant results are in bold characters..
Figure 4.  Receiver Operator 
Characteristics (ROC) curves of the NM 
area for: a) differentiating between de 
novo PD versus 2-5 year PD patients (A); 
b) de novo PD versus LSPD patients (B); c) 
2-5 year PD versus LSPD patients (C); d) PD 
versus controls; 
Figure 5. CR values in in de novo PD patients, 
2-5 year PD patients, LSPD patients and 
controls for the SN internal region (A) and 
lateral region (B). 
Figure 1. Contrast ration assessment
Figure 3. ROC curves of NM area  
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Figure 3. Median area values of the SN 
high intensity region on NM-sensitive 
MRI in de novo PD patients, 2-5 year PD 
patients, LSPD patients and controls
Figure 2. Neuromelanin (NM) area selection on NM sensitive magnetic resonance images of the SN of a healthy control (a), a 
de novo PD patient (b) and a LSPD patient.
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